Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

23.97 +0.62 (+2.66%)
Streaming Delayed Price Updated: 11:48 AM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March
From Pacira BioSciences
Via GlobeNewswire
News headline image
For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals. ↗
PACIRA BIOSCIENCES INC has a stellar value proposition. NASDAQ:PCRX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
News headline image
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
What 8 Analyst Ratings Have To Say About Pacira BioSciences ↗
 
Via Benzinga
News headline image
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Pacira to Report 2024 Financial Results on Thursday February 27, 2025
From Pacira BioSciences
Via GlobeNewswire
News headline image
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate ↗
Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery. 
Via Benzinga
News headline image
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ROSEN, LEADING INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued. ↗
Consider PACIRA BIOSCIENCES INC as a top value stock. NASDAQ:PCRX shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced. 
Via Chartmill
News headline image
PCRX Stockholders Should Contact Shareholder Rights Firm Robbins for Information About the Class Action Against Pacira BioSciences, Inc.
From Robbins LLP
Via GlobeNewswire
News headline image
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Pacira Announces Updates to Board of Directors
From Pacira BioSciences
Via GlobeNewswire
News headline image
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments
From Pacira BioSciences
Via GlobeNewswire
News headline image
PCRX Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Pacira BioSciences, Inc.
From Robbins LLP
Via GlobeNewswire
News headline image
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.